Apr 24, 2023
Jeff Liter is the CEO and Founder of Luminary Therapeutics, which is using gamma delta cells in their approach to CART-T cell therapy because of the ability of these cells to infiltrate solid tumors. With a multi-targeting system, Luminary has demonstrated promise treating multiple types of solid tumors, blood tumors,...
Apr 24, 2023
Jeff Liter is the CEO and Founder of Luminary Therapeutics, which is using gamma delta cells in their approach to CART-T cell therapy because of the ability of these cells to infiltrate solid tumors. With a multi-targeting system, Luminary has demonstrated promise treating multiple types of solid tumors, blood tumors,...
Mar 20, 2023
Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to...
Mar 20, 2023
Dr. Tina Albertson is the Chief Medical Officer and Head of Development at Lyell, using cell therapy to fight solid tumors through epigenetic and genetic reprogramming methods. Tumors have their own mechanisms for suppressing the immune system. These are the types of pathways Lyell is targeting with their engineering to...
Feb 2, 2023
Akihiro Ko is the CEO and Co-Founder of Elixirgen Therapeutics, which was founded with the mission of treating patients using RNA technology. Their c-srRNA, controllable self-replicating RNA, technology is being applied to telomere biology disorders where patients have inherited short telomeres and a failure to develop...